Latest / Eyewire News: The Podcast

Kodiak Plans to Submit BLA for Zenkuda After Phase 3 Data
Kodiak Sciences meets its primary endpoint in a phase 3 trial for its DME drug candidate clearing the way for a regulatory submission; the European Commission approves Roche’s Susvimo for wet AMD; and Merck announces topline results from a pivotal phase 2b/3 trial evaluating two doses of its DME treatment candidate.
Learn more about your ad choices. Visit megaphone.fm/adchoices
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.